MedTrace Logo

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

NCT04176718 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-10-07

No results posted yet for this study

Summary

This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma.

This research study involves two study drugs and two standard of care drugs.

* The names of the study drugs involved in this study are:

* Carfilzomib
* Daratumumab
* The names of the standard of care drugs involved in this study are:

* Dexamethasone
* Pomalidomide

Conditions

  • Multiple Myeloma
  • Refractory Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Relapse

Interventions

DRUG

Daratumumab

predetermined dose, intravenously, at predetermined times per cycle

DRUG

Carfilzomib

predetermined dose, intravenously, give 3 times per cycle

DRUG

Pomalidomide

predetermined dose, orally, daily per cycle

DRUG

Dexamethasone

predetermined dose, orally, given 8 times per cycle

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Andrew Yee, MD

    lead OTHER

Principal Investigators

  • Andrew J Yee, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-18
Primary Completion
2027-05-31
Completion
2028-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04176718 on ClinicalTrials.gov